2500
vs
H
Hang Seng (Hong Kong)
2500
Over the past 12 months, Venus Medtech Hangzhou Inc has underperformed Hang Seng (Hong Kong), delivering a return of -58% compared to the Hang Seng (Hong Kong)'s +7% growth.
Stocks Performance
2500 vs Hang Seng (Hong Kong)
Performance Gap
2500 vs Hang Seng (Hong Kong)
Performance By Year
2500 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Venus Medtech Hangzhou Inc
Glance View
Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2019-12-10. The firm's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8 / TAV8 and TriGUARD3 Cerebral Embolic Protection Device.